
N4 PHARMA PLC
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
N4P | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYW8QM32
- LEI:
- 213800I841D2RKMFK955
- Country:
- United Kingdom
- Address:
- 6TH FLOOR, EC3V 0HR LONDON
- Website:
- https://n4pharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
N4 Pharma PLC is a pre-clinical biotechnology company specializing in the development of novel drug and vaccine delivery systems. The company's primary focus is its proprietary Nuvec® technology, a silica nanoparticle platform designed for the intracellular delivery of nucleic acids such as pDNA and mRNA. Nuvec® aims to enable and enhance advanced therapies, particularly for cancer and other diseases, by improving the performance and delivery of gene-based treatments. N4 Pharma's business model involves advancing its technology pipeline and forming strategic partnerships with pharmaceutical and biotechnology companies to apply its delivery system to new and existing therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Date | Filing | Language | Size | Actions | |
---|---|---|---|---|---|
2025-09-23 08:00 |
Regulatory News Service
Partnership with University of Strathclyde’s CMAC
|
English | 19.6 KB | ||
2025-09-22 08:00 |
Regulatory News Service
N4 Pharma’s Nuvec® Targets Lung Cancer Cells
|
English | 17.5 KB | ||
2025-09-19 08:00 |
Report Publication Announcement
Notice of Results, Analyst & Investor Presentation
|
English | 15.8 KB | ||
2025-09-11 08:00 |
Regulatory News Service
Investor Event and Presentation
|
English | 13.9 KB | ||
2025-07-30 14:55 |
Regulatory News Service
Article on Nuvec®’s Potential in RNA Therapeutics
|
English | 13.4 KB | ||
2025-07-14 08:00 |
Investor Presentation
Investor Webinar
|
English | 14.4 KB | ||
2025-06-30 08:00 |
Pre-Annual General Meeting Information
AGM Statement
|
English | 25.8 KB | ||
2025-06-06 08:00 |
Annual Report
Final Results, Annual Report and Notice of AGM
|
English | 604.1 KB | ||
2025-05-27 08:00 |
Board/Management Information
Establishment of New Senior Leadership Team
|
English | 19.2 KB | ||
2025-05-23 13:37 |
Major Shareholding Notification
TR-1: Notification of major holdings
|
English | 52.3 KB | ||
2025-05-21 17:11 |
Major Shareholding Notification
Holding(s) in Company
|
English | 50.9 KB | ||
2025-05-15 16:13 |
Regulatory News Service
Change of Registered Address
|
English | 12.2 KB | ||
2025-05-09 09:24 |
Major Shareholding Notification
Holding(s) in Company
|
English | 50.7 KB | ||
2025-04-29 17:25 |
Major Shareholding Notification
Holding(s) in Company
|
English | 52.1 KB | ||
2025-04-29 12:05 |
Major Shareholding Notification
Holding(s) in Company
|
English | 52.3 KB |
Automate Your Workflow. Get a real-time feed of all N4 PHARMA PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for N4 PHARMA PLC via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |